Varenicline Effects In Schizophrenic Smokers

Completed · Phase 4

Conditions studied: Schizophrenia, Tobacco Use Disorder, Nicotine Dependance

In brief

This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are assessed on subjective and objective measures of smoking, selected cognitive measures, and special chemical measures, during baseline testing and during 8 weeks of treatment with varenicline (1-2 mg/day).

Key facts

Study ID

NCT00548470

Run by

Nathan Kline Institute for Psychiatric Research

People needed

14

Starts

2007-06-01

Expected to finish

2010-12-01

Last updated by the study team

2018-09-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical Diagnosis of Schizophrenia or Schizoaffective Psychosis
• Recent History of Cigarette smoking
• Ages 18-65

Where it is running

• Manhattan Psychiatric Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.